Page numbers in *italics* denote figures, those in **bold** denote tables.

A

**abciximab** 101

**abortion**

  recurrent 160–1
  thromboprophylaxis 156

**acenocoumarol** 66, 85

**acetylsalicylic acid (ASA)** 7, 14, 105–6, 107

**DIC** 187

**ischemic heart disease** 97

**NSTEMI** 97

**PCI** 99

prolonged bleeding time 64

prophylaxis against reocclusion 125

repeated miscarriage 161

secondary stroke prevention 121

**STEMI** 98

venous thrombosis in pregnancy 135

**acidosis**, correction of 57

**Actilyse** see tissue plasminogen activator (t-PA), recombinant

**activated partial thromboplastin time (APT time)** 15

prolonged 65–6

venous thrombosis 79

activated protein C (APC) 3

resistance 25–6

acute coagulopathy of trauma and shock (ACoTS) 56

acute fatty liver of pregnancy 153

acute phase reactants 6, 23, 27, 28, 34, 94, 96, 184

**ADAMTS-13** 34–5, 153, 190

**ADP (P2Y12) receptor antagonists** 106

  see also clopidogrel; prasugrel; ticagrelor

**amyloidosis** 66

**angina pectoris, unstable** 97–8

**angiography** 59

  magnetic resonance 74, 78
  pulmonary 78

**anti-factor Xa assay** 20

**anti-vitamin K treatment** see vitamin-K antagonists

**anticoagulants** 23–4

  new see new oral anticoagulants
  venous thrombosis 80–4
  in pregnancy 135–6

  see also vitamin-K antagonists

**antiphospholipid syndrome** 141

epidural/spinal analgesia 150
alpha₂-antiplasmin see plasmin inhibitor
antiplatelet drugs 105–10, 107
ADP (P₂Y₁₂) receptor antagonists 106
ASA see acetylsalicylic acid
benefit-risk assessment 108–9
combined therapy 108
GPIIb/IIIa inhibitors 14, 98, 106
phosphodiesterase inhibitors 108
see also thrombolytic therapy
antithrombin 19–20
blood sampling 148
children 148, 163, 164
deficiency 145
pregnancy 130, 145
antithrombin concentrate 29, 138, 144, 145, 148, 155, 186–7
antithrombotics
see new oral anticoagulants
combined therapy 108
secondary stroke prevention 121
see also antiplatelet drugs; thrombolytic therapy
APC see activated protein C
APC-PCI complex 34
apixaban 93
clinical pharmacology 112
clinical trials 116–18
apolipoprotein A1 37–8
APT (APT-time) see activated partial thromboplastin time
arterial blood gases 58
pulmonary thromboembolism 78
arterial thrombosis 96
children 178–9
secondary prophylaxis 101
artificial insemination (IVF) 160
ASA see acetylsalicylic acid
atrial fibrillation 102–3
CHA₂DS₂-VASc score 102–3
CHAĐS₂ score 102
planned electroconversion 103
stroke 122
TIA 122
B
Bernhard-Soulier syndrome 26, 64
children 170
bivalirudin 100, 177
bleeding disorders
blood sampling 54
children 166–72
acquired bleeding tendency 170–2
coagulation factor deficiencies 167–70
newborns 166–7
critical bleeding 56–61
hepatitis risk 49
hereditary 41–55
rare 51–4
risk charts 54–5
surgery 47
tooth extraction 47
see also specific disorders
bleeding tendency 62–7
children 167, 170–2
diagnosis 62–3
elevated INR 66
investigations 66–7
prolonged APT time 65–6
screening analysis 64
thrombocytopenia 64–5
bleeding time 11, 14, 26, 43, 51, 54, 61, 63, 92, 112, 149, 150, 161, 165, 170, 187
prolonged 64, 83
blood group 7, 10, 58, 83, 89, 161
blood malignancies 61
blood sampling 6–10
bleeding disorders 54
conditions 6–7
genetic analysis 10
patient preparation 7–8
plasma analysis 8–9  
referrals 8  
technique 9–10  
time of 7–8  

brain natriuretic peptide 134  
breastfeeding, thrombosis prophylaxis 138  
Budd-Chiari syndrome 75

C  
C-reactive protein 17, 36  
C1-esterase inhibitor 33  
caesarean section,  
thromboprophylaxis 147  
cardiac enzymes 78  
cerebral infarction 138  
cerebral venous thrombosis 123, 143  
CHA2DS2-VASc score 102–3  
CHADS2 score 102  
children 162–81  
bleeding disorders 166–72  
acquired bleeding tendency 170–2  
coagulation factor deficiencies 167–70  
newborns 166–7  
coagulation screening 165  
hemostatic variables 163, 164  
thromboembolic disorders 172–81  
artrial thrombosis 178–9  
prothrombotic risk factors 177–8  
stroke 179–81, 180  
thrombolytic therapy 176–7  
venous thrombosis 172–6, 175  
cilostazol 108  
Claus method 17  
clopidogrel 7, 14, 107  
ischemic heart disease 97–8  
PCI 99  
prolonged bleeding time 64  
prophylaxis against reocclusion 125  
secondary stroke prevention 121  
Coagucheck 32  
coagulation factors 20–3  
concentrates see factor concentrates  
deficiencies in children 167–70  
pregnancy 131  
see also individual coagulation factors  
compression stockings 79, 140–1, 143  
computed tomography (CT)  
pulmonary embolism 77, 134  
spiral 77  
venous thrombosis 74  
cordocentesis 152  
coronary artery stenting 100–1  
creatinine 58, 80, 83, 98, 112, 113, 120, 136, 186  
critical bleeding 56–61  
choice of plasma 58  
complicating factors 61  
definition 56  
local procedures 59  
management 57–8  
cryoprecipitates 60  
desmopressin 60  
fibrinogen concentrate 59  
local hemostatic drugs 60  
prothrombin complex concentrate 59  
recombinant factor VIIa 59–60  
tranexamic acid 60  
transfusion coagulopathy 56–7  
cryoprecipitates, critical bleeding 60  
Cyklokapron see tranexamic acid  
cytokines 36–7  
D  
D-dimer 5, 18–19  
point-of-care testing 32  
pregnancy 130  
venous thrombosis 74–5
dabigatran etexilat 80, 93
clinical pharmacology 113–14
clinical trials 116–18
heart disease 104
renal elimination 118, 119–20
side-effects 119
dalteparin (Fragmin) see low molecular weight heparin
danaparoid 138, 177, 189, 190
depth venous thrombosis see venous thrombosis
desmopressin 53–4, 83
contraindications and side-effects 54
critical bleeding 60
dextran 93, 125
DIC 187
gynecologic surgery 157
diabetes mellitus 101
DIC 17, 18, 64, 96, 153, 182–8
clinical features 183–4
definition 182
factor VIII in 21
laboratory diagnosis 184
pathophysiology 182–3
treatment 185–8, 185
monitoring 184–5
dipyridamole 108
secondary stroke prevention 121
disseminated intravascular coagulation see DIC
diurnal variation 6

E
ecarin clotting time 33, 113, 118
ECG, pulmonary embolism 78
echocardiography, pulmonary embolism 78
edoxaban 93, 116, 117
elastase 33
electroconversion 103
Eliquis see apixaban

ELISA, heparin antibodies 27
emergency situations
DIC see DIC
new oral anticoagulants 119–20
see also critical bleeding
emergency trauma packages 58
endogenous thrombin potential (ETP) 31
enoxaparin (Clexane) see low molecular weight heparin
epidural/spinal analgesia 148–50
antiphospholipid syndrome 150
ASA medication 149
hemophilia carriers 150
high-dose prophylaxis 148–9
ITP 149
platelet function deficiency 149
pre-eclampsia 149
von Willebrand disease 149
eptifibatide 98, 106
essential thrombocytosis/thrombocythemia 152
estrogen 6–7

F
factor concentrates 43–4
critical bleeding 58, 59–60
DIC 187
recommended concentrations 45–7
factor II see prothrombin
factor V 3, 15, 21
children 163, 164
pregnancy 131
factor V Leiden 10, 31, 94, 161
factor VII 3, 6, 20, 21
antibody 23
children 163, 164
deficiency 15
pregnancy 131
factor VIIa 21, 59–60, 123
recombinant 59–60
factor VIII 3, 6, 10, 15, 21
  antibodies 168
  children 163, 164
  concentrates 43–4, 45–7
  deficiency see hemophilia type A
  pregnancy 131
factor IX 15, 21
  antibody 23
  children 163, 164
  concentrates 44, 45–7
  deficiency see hemophilia type B
factor X 15, 20
  children 163, 164
  pregnancy 131
factor Xa 8
factor Xa inhibitors 93
  bleeding during therapy 91
  see also new oral anticoagulants
factor XI 21
  children 163, 164
  deficiency 66
factor XII 21–2
  children 163, 164
  deficiency 66
factor XIII 22
  concentrates 60
  deficiency 15
fibrin 3
  pregnancy 130
  soluble 18
fibrin-gel structure 32
fibrinogen 15, 17–18, 36
  children 163, 164
  pregnancy 130
fibrinogen concentrate 59
  DIC 187
fibrin(ogen) degradation products 5, 18, 183
fibrinolysis 27–8
Fibrogammin 60
fibronectin 37, 154
fondaparinux 80, 93, 98, 99
FV-Leiden mutation 31

G

gastrointestinal hemorrhage, anticoagulant-induced 119
genetic analysis 10, 29–31
Glanzmann thromboasthenia 26, 52, 64
  children 170
glycoprotein IIb/IIIa inhibitors 14, 98, 108
  see also abciximab; eptifibatide; tirofiban
GPIIb/IIIa inhibitors see glycoprotein IIb/IIIa inhibitors
gum bleeding 50
gynecologic surgery 156–60
  hormone replacement therapy 157, 159–60
  oral contraceptives 157–9

H

heart disease 97–104
  anticoagulant therapy 104
  atrial fibrillation 102–3, 119, 122
  ischemic heart disease 97–102
heart valve prostheses 103, 139–40, 140
HELLP syndrome 153
hematocrit 6, 14, 45, 57, 58, 165, 170
  venous thrombosis 79
hematuria 49–50, 52, 53, 173
  macroscopic 51
hemoglobin 57, 79, 120, 136, 156
hemolytic uremic syndrome (HUS) 35, 190
hemophilia 41–2
  analgesics permitted in 48
  anti-inflammatory drugs permitted in 48
  children 167–9
  genetic analysis 29–30
  pregnancy 150–1
hemophilia (continued)
prophylaxis 47
surgery 47
tooth extraction 47
treatment 44–7, 50–2
side-effects 48–9
type A 42
factor VIII concentrates 21, 43, 45–7
type B 42
factor IX concentrates 44, 45–7

hemostasis 3–5, 4
initiation phase 5
priming phase 5
propagation phase 5

heparin
antibodies 27
dosage and dilution 136
low molecular weight see low molecular weight heparin
monitoring 7
unfractionated see unfractionated heparin

heparin co-factor II 33
heparin-induced platelet aggregation 26
heparin-induced thrombocytopenia 20, 177, 188–90, 189

hepatitis, and bleeding disorders 49
hereditary bleeding tendency 167
Hirudoid 82
homocysteine 37
hormone replacement therapy 95, 157, 159–60
hypercoagulation 96
markers of 29
hypocalcemia 57

I
idiopathic thrombocytopenic purpura
children 171
epidural/spinal analgesia 149
pregnancy 151–2
INR see international normalized ratio
international normalized ratio (INR) 16
elevated 66
venous thrombosis 80
vitamin K antagonist therapy 88–90
International Sensitivity Index (ISI) 16
ischemia, acute, thrombolytic therapy 126
ischemic heart disease 97–102
PCI 99–100
stable 97
STEMI 98–9
unstable angina pectoris 97–8
ITP see idiopathic thrombocytopenic purpura

K
Kawasaki disease 179
kidney failure 61
kininogen 21–2

L
laboratory investigations 11–38
genetic analysis 10, 29–31
hemostatic assays and bedside methods 31–2
hypercoagulation markers 29
nomenclature 11–13
platelet-activating predictors 35–8
reference intervals 13
research studies 32–5
screening analyses 13–20
special analyses 20–8
*see also specific investigations*

**Lixiana** *see* edoxaban

**lipoprotein (a)** 37–8

**liver failure** 61

**LMH** *see* low molecular weight heparin

**local anesthesia, vitamin K antagonist therapy** 89

**low molecular weight heparin (LMH)** 20, 80, 115

- allergy 138
- bleeding complications 82–3, 91, 176–7

**DIC** 185

- gynecologic surgery 156–7
- heart valve prostheses 140
- NSTEMI 98
- STEMI 99

- venous thrombosis 81
  - children 175
  - pregnancy 135, 136–7, 142

**lupus anticoagulant** 24, 25, 96, 141, 143

**M**

**magnetic resonance angiography**

- pulmonary embolism 78
- venous thrombosis 74

**magnetic resonance imaging (MRI)** 121, 134

Marcoumar *see* phenprocoumon

**massive transfusion** 58

**menorrhagia** 50, 161, 169

**microparticles** 36

**miscarriage** *see* abortion

**multiple impedance aggregometry** 14

**mutation analyses** 8

**myocardial infarction**

- anticoagulant-induced 119
- non-ST-elevation *see* NSTEMI
- ST-elevation *see* STEMI

**N**

**new oral anticoagulants (NOACs)** 111–20

- antidotes 120
- characteristics 118–19
- clinical aspects 114–16
- clinical pharmacology 111–14
- clinical trials 116–18
- emergency situations 119–20
- indications
  - heart disease 104
  - stroke 122
- therapeutic monitoring 114
  *see also individual drugs*

**newborns**

- bleeding in 166–7
- hemostatic variables 163, 164
  *see also* children

**nonsteroid anti-inflammatory drugs** *see* NSAIDs

**nose bleeds** 50

NovoSeven *see* factor VIIa

NSAIDs 7, 108

- DIC 187
  - prolonged bleeding time 64
  - thrombophlebitis 82

NSTEMI 97–8

- PCI 100

**O**

**obstetrical bleeds** 57, 155–6

**obstetrics and gynecology**

- artificial insemination (IVF) 160
- delivery 144
  - caesarean section 147
  - vaginal 148
- gynecologic surgery 156–60
- menorrhagia 50, 161, 169
- pregnancy *see* pregnancy
- puerperium
  - postpartum bleeding 57, 155–6
  - thromboprophylaxis 138, 144–5
- repeated miscarriage 160–1
Octostim see desmopressin
oral contraceptives 95, 157–9
overall hemostatic potential
(OHP) 31
Owren reagents 16

P
P-selectin 36
PA see plasminogen activator
t-PA-PAI complex 33
PAI see plasminogen
activator-inhibitor
PCI see percutaneous coronary
intervention; protein C
inhibitor
pelvic thrombosis 138
percutaneous coronary
intervention (PCI) 98,
99–100
primary 100
STEMI 100
percutaneous transluminal
angioplasty 125
peripheral artery surgery 125–6
peri- and postoperative
treatment 125
peripheral vascular surgery 125
phenprocoumon 66, 85
phlebography 74
pregnancy 132, 133
phosphodiesterase inhibitors 108
phospholipid antibodies 24, 96,
143
repeated miscarriage 160–1
plasma
analysis 8–9
choice of 58
DIC 185, 186
plasmin 5
plasmin inhibitor 27
plasmin-plasmin inhibitor
complex 32
plasminogen 27
plasminogen activator-inhibitor-1
(PAI-1) 28
pre-eclampsia 154
pregnancy 130
plasminogen activator-inhibitor-2
(PAI-2) 33–4
pregnancy 130
platelet aggregation 14, 26
heparin-induced 26
platelet concentrate 15, 59, 109,
151, 155–6, 185
platelet count 15, 63, 67
low see thrombocytopenia
massive bleeding 58
pregnancy 130
venous thrombosis 79, 91
platelet disorders
children 170
epidural/spinal analgesia 149
ITP 149, 151–2
see also specific disorders
platelet factor 4 35
platelet function tests 26–7
platelet transfusion 109–10
Plavix see clopidogrel
point-of-care testing 32
portal vein thrombosis 75,
173–4
Pradaxa see dabigatran etexilate
prasugrel 14, 98, 107
pre-eclampsia 149, 152–3
prophylaxis 153–4
pre-term infants, hemostatic
variables 164
precerebral arteries,
dissection of 123
pregnancy 129–62
antithrombin 19
bleeding disorders 51
coagulation factors 131
complications 150–4
acute fatty liver of pregnancy
153
essential thrombocytosis/thrombocythemia 152
hemophilia and von Willebrand disease 150–1
ITP 151–2
pre-eclampsia 149, 152–4
thrombotic thrombocytopenic purpura 153
epidural/spinal analgesia 148–50
heart valve prostheses 139–40, 140
hemostatic variables 129, 130, 131
C-reactive protein 17, 130
D-dimer 19, 130
postpartum bleeding 57, 155–6
thromboembolic disorders 131–9
breastfeeding 138
puerperium 138, 144–5
recurring 145–7, 146
risk factors 141
special cases 138
thromboprophylaxis 140–8
antithrombin deficiency 145
at birth 144
ciaesarean section 147
LMH dose 142
puerperium 144–5
recurring thromboembolic disorders 145–7, 146
vaginal delivery 148
vitamin-K antagonists 145–7
pretest clinical probability scoring system (4Ts) 188, 189
prokallikrein 15, 21–2
protamine 125
protein C 25
children 163, 164
pregnancy 130
protein C inhibitor (PCI) 34
protein S 24–5
pregnancy 130
prothrombin 10, 14, 15, 20
children 163, 164
clinical suspicion 75–6, 76
incidence 71–2, 72
investigations 77–8
massive 139
pregnancy 131–8
diagnosis 132–5
treatment 134–8
prophylaxis 91–3, 124
treatment
thrombolytic therapy 83–91
unfractionated heparin 82
pulmonary scintigraphy 77
pulmonary X-ray 77
purpura fulminans 171
pulmonary embolism 75–9
children 174
clinical suspicion 75–6, 76
incidence 71–2, 72
investigations 77–8
massive 139
pregnancy 131–8
diagnosis 132–5
treatment 134–8
prophylaxis 91–3, 124
treatment
thrombolytic therapy 83–91
unfractionated heparin 82
R
radiation dose in pregnancy 133
raloxifen 160
referrals 8
reocclusion, thromboprophylaxis 125
REOROX 32
reteplase 83
retinal thrombosis 138
Riastap 59
rivaroxaban 93
clinical pharmacology 111–12
clinical trials 116–18
side-effects 119
ROTEM see thromboelastography

S
sampling see blood sampling
screening analyses 13–20
selective estrogen receptor modulators (SERMs) 160
septic coagulopathy 188
septic shock 184
Sintron see acenocoumarol
sinus venous thrombosis 177–8
Sonoclot 32
STEMI 98–9
thrombolysis in 99
stenting 80
 coronary artery 100–1
streptokinase 99
stroke 121–4
 atrial fibrillation 122
cerebral venous thrombosis 123
children 179–81, 180
risk factors 180
secondary prevention 121
thrombolysis 122–3
surgery
bleeding disorders 47
gynecologic 156–60
peripheral artery 125–6
thrombosis prophylaxis 92
vitamin-K antagonist therapy 89–90

T
t-PA see tissue plasminogen activator
t-PA-PAI-1 complex 33
tamoxifen 160
TEG see thromboelastography
tenecteplase 83, 99
therapeutic monitoring 114
thrombectomy 80
thrombin 3
thrombin activatable fibrinolysis inhibitor (TAFI) 5, 34
thrombin inhibitors 8, 93
 bleeding during therapy 91
thrombin time 33
thrombin-antithrombin (TAT) complexes 5, 29, 129
 pregnancy 130
thrombocytopenia 15
 acquired 65
causes 64–5
children 170–1
heparin-induced 20, 177, 188–90, 189
hereditary 65
thrombocytosis 15
thromboelastography 32
thromboembolic disorders
children 172–81
 arterial thrombosis 178–9
prothrombotic risk factors 177–8
stroke 179–81, 180
thrombolytic therapy 176–7
venous thrombosis 172–5, 175
 genetic analysis 31
pregnancy 131–9
 breastfeeding 138
puerperium 137–8, 144–5
recurring 145–7, 146
risk factors 141
 special cases 138
venous thrombosis/pulmonary embolism 71–93
thromboembolic tendency 94–6
thromboglobulin 35
thrombolytic therapy 83–91
 acute ischemia 126
children 176–7
pulmonary embolism 84
recombinant t-PA 84–5
STEMI 99
stroke 122–3
venous thrombosis 83
vitamin-K antagonists 79, 85–91
see also antiplatelet drugs
thrombomodulin 3, 37
thrombophilia 132
blood sampling of children 148
in pregnancy 131–2, 141
repeated miscarriage 160–1
thrombophlebitis 73, 75
treatment 82
thromboprophylaxis
abortion 156
breastfeeding women 138
compression stockings 79, 140–1, 143
gynecologic surgery 156–60
pregnancy 140–8
antithrombin deficiency 145
at birth 144
caesarean section 147
LMH dose 142
puerperium 144–5
recurring thromboembolic disorders 145–7
vaginal delivery 148
vitamin-K antagonists 145–7
reocclusion 125
support stockings 140–1
surgery 92
thrombotic microangiopathies 190
thrombotic thrombocytopenic purpura 153, 190
thrombosis-stimulating hormone 134
ticagrelor 98, 100, 107
tinzaparin see low molecular weight heparin
tirofiban 98
tissue factor pathway inhibitor 5, 35
tissue glue (Tisseel) 188
tissue plasminogen activator (t-PA) 5, 27–8
recombinant 84, 122
venous thrombosis 83
tooth extraction
bleeding disorders 47
vitamin-K antagonist therapy 89
tranexamic acid 47, 50, 51
contraindications 51
critical bleeding 60
DIC 185, 187–8
hemophilia 131, 168
stroke 123
thrombocytopenia 171
von Willebrand disease 131
transfusion coagulopathy 56–7
transient ischemic attacks 121–4
and atrial fibrillation 122
recurrent 124
triple therapy 101–2, 108
U
ultrasound
pulmonary embolism 174
venous thrombosis 74
unfractionated heparin (UFH) 20
bleeding complications 82–3, 91, 176–7
venous thrombosis 82
children 174, 175
pregnancy 134–5, 136
V
V/Q SPECT 134
varicose veins 75
vena cava filter 80
venous thromboembolism 95–6
see also pulmonary embolism; venous thrombosis
venous thrombosis 72–5
arm 75
Budd-Chiari syndrome 75
cerebral 124
children 172–6, 175
diagnosis 72–3, 73
differential diagnosis 73
incidence 71–2, 72
investigations 74–5
mesenteric veins 75
patients with malignancy 81
portal veins 75, 173–4
pregnancy 131–9
diagnosis 132–5
treatment 134–8
prophylaxis 91–3, 124
superficial thrombophlebitis 75
treatment 79–84
nonpharmacologic 79–80
pharmacologic 80–3
surgical 80
vitamin K
deficiency in newborns 166–7
reduced absorption 61
vitamin-K antagonists 7–8, 79, 85–91, 85, 115
children 175–6
INR during therapy 88–90
intensity of treatment 85–7
mechanisms for interaction with 86–7, 86
overdose 90–1
pregnancy 135, 145–7
prophylactic 93
prothrombin time 90
stroke 122
termination of treatment 87
see also individual drugs
von Willebrand disease 22, 42–3, 64
children 169
epidural/spinal analgesia 150
genetic analysis 30
pregnancy 150–1
treatment 44–5, 50–2
side-effects 48–9
von Willebrand factor 6, 10, 22, 36
antibody 23–4
children 163, 164
concentrates 44
deficiency see von Willebrand disease
pregnancy 131
von Willebrand factor cleaving protease see ADAMTS-13
W
warfarin 85, 115
bleeding complications 176–7
heart valve prostheses 140
X
Xarelto see rivaroxaban
ximelagatran 115